Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
McKinsey

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

SPRX-3 Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Sprx-3 patents expire, and what generic alternatives are available?

Sprx-3 is a drug marketed by Solvay and is included in one NDA.

The generic ingredient in SPRX-3 is phendimetrazine tartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.

Summary for SPRX-3
Drug patent expirations by year for SPRX-3
Synonyms for SPRX-3
(2R,3R)-2,3-bis(oxidanyl)butanedioic acid; (2S,3S)-3,4-dimethyl-2-phenyl-morpholine
(2R,3R)-2,3-dihydroxybutanedioic acid; (2S,3S)-3,4-dimethyl-2-phenylmorpholine
(2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)-tartrate (1:1)
21102-82-9
2233-26-3
238P764
50-58-8
6985IP0T80
A828189
AC1L3R57
AC1Q5R36
Adipost
ALPHAZINE
Bontril (TN)
BONTRIL PDM
CAM-METRAZINE
D-3,4-Dimethyl-2-phenyl-morpholine tartrate
D02080
DI-METREX
DTXSID70198165
EINECS 200-051-0
K631
LS-92795
MELFIAT
MELFIAT-105
Metra
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1) (8CI)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S-trans)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S,3S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, tartrate, D-
PHENAZINE-35
Phendimetrazine hydrogen tartrate
Phendimetrazine tartrate
Phendimetrazine tartrate (USP)
Phendimetrazine tartrate [USAN]
Phendimetrazine tartrate [USP]
phendimetrazine tartrate, (2S-trans(R-(R*,R*)))-isomer
Prelu 2
Prelu-2
SCHEMBL160375
Sodium alginate, viscosity ~100mp.s
SPRX
SPRX-105
Statobex
STATOBEX-G
UNII-6985IP0T80
X-TROZINE L.A
X-trozine L.A.

US Patents and Regulatory Information for SPRX-3

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Solvay SPRX-3 phendimetrazine tartrate CAPSULE;ORAL 085897-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
McKesson
Merck
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.